OXON’s new RWE services and developments at ISPE Annual Meeting

August 24-28, 2024 | Estrel Congress Center | Berlin, Germany

OXON will be supporting ICPE 2024 as an exhibitor, showcasing expanded services and new developments in RWE. 

We are excited to announce that OXON’s Epidemiology team will be presenting and exhibiting at the ISPE 2024 Annual Meeting in Berlin, from August 24-28. We would be delighted to meet you at Booth #405 and explore how we can support you with our expanded  services, designs and new developments.

OXON is a leading provider of global data collection and secondary data RWE studies and strategy in all major therapy areas, orphan conditions, pregnancy and vaccines for Clinical Development, Safety and Market Access.

Visit us during the conference. Our RWE team will inform you about Real-World Evidence (RWE) cost-effective solutions, services and designs: 

• Use of the Pocock ‘Win Ratio’ (approved by FDA/EMA in trials) to increase statistical power (and success!) in RWE comparative studies:
  • External controls in rare disease/difficult-to-enrol trials with small sample sizes.
  • Primary and secondary RWE studies with low rate of endpoints.
• Comprehensive and Integrated RWE strategy for rare diseases:
  • Planning, design, execution and analysis of external controls using the ‘Win Ratio’.
  • Planning, design, conduct and analysis of phase 1-3 trials in rare diseases using the ‘Win Ratio’.
• ‘End-to-end’ risk minimisation/REMS service: development, distribution, evaluation.
• Global capability for data collection studies for infectious, as well as chronic diseases, for vaccines and drugs: Europe, N. America, Asia, LATAM, Africa and the Middle East.
• Access to new data sources.
• Health economic modelling.

If you are attending, do not miss these two posters, co-authored and by our RWE generation team, to be presented in Session A on Monday, August 26, Convention Hall II:

• 015) Estimating Prevalence of Moderate-to-Severe Systemic Lupus Erythematosus: A Literature Review.
• (024) Mortality in an Eosinophilic Granulomatosis with Polyangiitis (EGPA) Incident Cohort: A Retrospective Study in England.

We look forward to connecting with you at the conference!